ALTSA: NH #2021-020; ALTSA: ALF #2021-013; Monoclonal Antibody Infusion Treatment for COVID-19

ALTSA: NH #2021-020; ALTSA: ALF #2021-013; Monoclonal Antibody Infusion Treatment for COVID-19

Residential Care Services released a Dear Provider Letter about the plan for Monoclonal Antibody Infusion Treatment for COVID-19 in long-term care.

On November 21, 2020, the Food and Drug Administration issued an emergency use authorization for use of monoclonal antibodies (mAb) to treat mild to moderate COVID-19 in certain people. Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses. Casirivimab and Imdevimab are monoclonal antibodies that are designed to block the SARS-CoV-2 virus’ attachment and entry into human cells. For more information about the treatment, including the Emergency Use Authorizations for Casirivimab and Imdevimab, follow this link.

 

Questions?

Contact:

Laura Hofmann, MSN, RN – Director of Clinical and Nursing Facility Regulatory Services
c: 425-231-4804

PrintArchiveLibrary

March 1, 2021